{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:48:15Z","timestamp":1792622895115,"version":"4.5.0"},"reference-count":46,"publisher":"Akademiai Kiado Zrt.","issue":"29","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,7,20]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az eml\u0151daganat kezel\u00e9se sor\u00e1n alkalmazott\n                    sug\u00e1rter\u00e1pia egyik gyakori sz\u00f6v\u0151dm\u00e9nye a sug\u00e1rz\u00e1s \u00e1ltal kiv\u00e1ltott t\u00fcd\u0151k\u00e1rosod\u00e1s.\n                    A perif\u00e9ri\u00e1s v\u00e9rk\u00e9p param\u00e9tereinek esetleges predikt\u00edv szerepe a sug\u00e1rz\u00e1s okozta\n                    t\u00fcd\u0151k\u00e1rosod\u00e1s kialakul\u00e1s\u00e1ban jelenleg kev\u00e9ss\u00e9 ismert.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    C\u00e9lunk annak vizsg\u00e1lata volt, hogy a\n                    sug\u00e1rkezel\u00e9s ut\u00e1n kialakul\u00f3 radiog\u00e9n t\u00fcd\u0151k\u00e1rosod\u00e1s \u00f6sszef\u00fcgg\u00e9sben \u00e1ll-e a\n                    perif\u00e9ri\u00e1s v\u00e9rk\u00e9p bizonyos param\u00e9tereivel.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    Retrospekt\u00edv vizsg\u00e1latot v\u00e9gezt\u00fcnk 94, I\u2013III. st\u00e1dium\u00fa eml\u0151daganatos betegn\u00e9l,\n                    akik sug\u00e1rkezel\u00e9sen, kemoter\u00e1pi\u00e1n \u00e9s\/vagy hormonkezel\u00e9sen estek \u00e1t. A radiog\u00e9n\n                    t\u00fcd\u0151k\u00e1rosod\u00e1s diagn\u00f3zis\u00e1t k\u00e9palkot\u00f3 vizsg\u00e1latok (CT, mellkasr\u00f6ntgen) igazolt\u00e1k.\n                    A perif\u00e9ri\u00e1s v\u00e9r param\u00e9terei k\u00f6z\u00fcl a feh\u00e9rv\u00e9rsejtsz\u00e1mot \u00e9s annak abszol\u00fat\n                    eloszl\u00e1s\u00e1t (lymphocyta, monocyta, neutrophil, eosinophil, basophil granulocyta),\n                    a v\u00f6r\u00f6sv\u00e9rtestsz\u00e1mot, a hemoglobinszintet, valamint a thrombocytasz\u00e1mot\n                    elemezt\u00fck. Vizsg\u00e1ltuk a neutrophil-lymphocyta ar\u00e1ny predikci\u00f3s szerep\u00e9t is. Az\n                    adatok statisztikai \u00f6sszehasonl\u00edt\u00e1s\u00e1ra a Mann\u2013Whitney-f\u00e9le U-tesztet\n                    alkalmaztuk.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A 94 betegb\u0151l 43-n\u00e1l igazol\u00f3dott\n                    radiog\u00e9n t\u00fcd\u0151k\u00e1rosod\u00e1s. A feh\u00e9rv\u00e9rsejtsz\u00e1m \u00e1tlaga szignifik\u00e1nsan magasabb volt a\n                    sug\u00e1rz\u00e1s okozta t\u00fcd\u0151k\u00e1rosod\u00e1ssal \u00e9rintett csoportban (8,03 \u00b1 8,07 G\/l), mint a\n                    negat\u00edv csoportban (7,11 \u00b1 6,19 G\/l; p = 0,001). A neutrophil granulocyta sz\u00e1m\n                    (5,17 \u00b1 4,77 G\/l\n                    <jats:italic>vs.<\/jats:italic>\n                    4,82 \u00b1 5,19 G\/l; p = 0,006), valamint a\n                    monocytasz\u00e1m (0,51 \u00b1 0,26 G\/l\n                    <jats:italic>vs.<\/jats:italic>\n                    0,47 \u00b1 0,36 G\/l; p&lt;0,001)\n                    eset\u00e9n is statisztikailag kimutathat\u00f3 elt\u00e9r\u00e9s volt l\u00e1that\u00f3 a pozit\u00edv \u00e9s a\n                    negat\u00edv csoportban. Hab\u00e1r a lymphocytafrakci\u00f3n\u00e1l nem tal\u00e1ltunk k\u00fcl\u00f6nbs\u00e9get, a\n                    neutrophil-lymphocyta ar\u00e1nyn\u00e1l m\u00e1r l\u00e9nyeges elt\u00e9r\u00e9st tapasztaltunk (3,62 \u00b1 3,04\n                    <jats:italic>vs.<\/jats:italic>\n                    3,13 \u00b1 3,45; p&lt;0,001). A v\u00f6r\u00f6sv\u00e9rtestsz\u00e1m (p =\n                    0,09), a hemoglobinszint (p = 0,166) \u00e9s a thrombocytasz\u00e1m (p = 0,677)\n                    vonatkoz\u00e1s\u00e1ban nem tal\u00e1ltunk szignifik\u00e1ns k\u00fcl\u00f6nbs\u00e9get.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Az emelkedett feh\u00e9rv\u00e9rsejtsz\u00e1m, neutrophil\n                    granulocyta \u00e9s monocyta\u00e9rt\u00e9kek egyar\u00e1nt predikt\u00edv szereppel b\u00edrhatnak a\n                    sug\u00e1rkezel\u00e9s sor\u00e1n kialakul\u00f3, sug\u00e1rz\u00e1s okozta t\u00fcd\u0151k\u00e1rosod\u00e1s vonatkoz\u00e1s\u00e1ban.\n                    Emellett a neutrophil-lymphocyta ar\u00e1ny is hasznos biomarkernek bizonyulhat az\n                    esetleges mell\u00e9khat\u00e1s szempontj\u00e1b\u00f3l. Eredm\u00e9nyeink hozz\u00e1j\u00e1rulhatnak a radiog\u00e9n\n                    t\u00fcd\u0151k\u00e1rosod\u00e1s patofiziol\u00f3gi\u00e1j\u00e1nak r\u00e9szletesebb meg\u00e9rt\u00e9s\u00e9hez, a pontosabb\n                    k\u00f6vetkeztet\u00e9sekhez azonban tov\u00e1bbi, nagyobb mintasz\u00e1m\u00fa vizsg\u00e1latok sz\u00fcks\u00e9gesek.\n                    Orv Hetil. 2025; 166(29): 1153\u20131159.\n                  <\/jats:p>","DOI":"10.1556\/650.2025.33336","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:43:53Z","timestamp":1753073033000},"page":"1153-1159","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Egyes laborat\u00f3riumi param\u00e9terek lehets\u00e9ges szerepe az eml\u0151tumor sug\u00e1rkezel\u00e9se okozta t\u00fcd\u0151k\u00e1rosod\u00e1s el\u0151rejelz\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"166","author":[{"given":"Tam\u00e1s","family":"Ungv\u00e1ri","sequence":"first","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsanett","family":"Ungv\u00e1rin\u00e9 Topcsiov","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6me","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Bassirani","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Kiss","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Skrapits","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Dankovics","sequence":"additional","affiliation":[{"name":"Vas V\u00e1rmegyei Markusovszky Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Szombathely, Markusovszky L. u. 5., 9700 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Olajos","sequence":"additional","affiliation":[{"name":"Szabolcs-Szatm\u00e1r-Bereg V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, Ny\u00edregyh\u00e1zi J\u00f3sa Andr\u00e1s Tagk\u00f3rh\u00e1z Ny\u00edregyh\u00e1za Magyarorsz\u00e1g"},{"name":"Ny\u00edregyh\u00e1zi Egyetem Ny\u00edregyh\u00e1za Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Kenessey I, Szil\u00e1gyi I, Dobozi M, et al. The role of National Cancer\n                    Registry in the assessment of Hungarian cancer epidemiology. [A Nemzeti\n                    R\u00e1kregiszter szerepe a hazai daganatos epidemiol\u00f3giai helyzet felm\u00e9r\u00e9s\u00e9ben.] Orv\n                    Hetil. 2024; 165: 925\u2013932. [Hungarian]","DOI":"10.1556\/650.2024.33062"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"S\u00e1rv\u00e1ry A, B\u00e1lint PCs, Gyulai A, et al. Retrospective examination of\n                    the Hungarian breast and cervical cancer screening programmes according to\n                    mortality and morbidity data. [A magyarorsz\u00e1gi eml\u0151- \u00e9s m\u00e9hnyaksz\u0171r\u00e9s\n                    retrospekt\u00edv vizsg\u00e1lat\u00e1nak jellemz\u0151i a hal\u00e1loz\u00e1si \u00e9s megbeteged\u00e9si adatok\n                    t\u00fckr\u00e9ben.] Orv Hetil. 2019; 160: 1948\u20131956. [Hungarian]","DOI":"10.1556\/650.2019.31518"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"B\u00e9res E, Nagy J, T\u00f3th J, et al. Standardized data on the incidence\n                    and mortality of female and male breast cancers in Hungary between 2000 and\n                    2016. [A n\u0151i \u00e9s a f\u00e9rfieml\u0151r\u00e1k standardiz\u00e1lt incidencia- \u00e9s mortalit\u00e1sadatai\n                    Magyarorsz\u00e1gon 2000 \u00e9s 2016 k\u00f6z\u00f6tt.] Orv Hetil. 2022; 163: 181\u2013186.\n                    [Hungarian]","DOI":"10.1556\/650.2022.32344"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"K\u00e1sler M, Polg\u00e1r Cs, Fodor J. Current status of treatment for\n                    early-stage invasive breast cancer. [A korai eml\u0151r\u00e1k kezel\u00e9s\u00e9nek aktu\u00e1lis\n                    helyzete.] Orv Hetil. 2009; 150: 1013\u20131021. [Hungarian]","DOI":"10.1556\/oh.2009.28615"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast\n                    cancer. Jpn J Clin Oncol. 2020; 50: 225\u2013229.","DOI":"10.1093\/jjco\/hyz213"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"M\u00e1trai Z, Guly\u00e1s G, Kunos Cs, et al. Minimally invasive breast\n                    surgery. [Minim\u00e1lisan invaz\u00edv eml\u0151seb\u00e9szet.] Orv Hetil. 2014; 155: 162\u2013169.\n                    [Hungarian]","DOI":"10.1556\/OH.2014.29783"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Koncz Z, Gy\u0151rffy Z, Girasek E, et al. Perioperative attitudes of\n                    breast cancer patients towards the complementary and alternative medicine based\n                    on a survey conducted at the National Institute of Oncology in Hungary.\n                    [Eml\u0151r\u00e1kban megbetegedett n\u0151k perioperat\u00edv viszonyul\u00e1sa a komplementer \u00e9s\n                    alternat\u00edv medicin\u00e1hoz az Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zetben v\u00e9gzett felm\u00e9r\u00e9s\n                    alapj\u00e1n.] Orv Hetil. 2022; 163: 350\u2013361. [Hungarian]","DOI":"10.1556\/650.2022.32380"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"S\u00e1volt \u00c1, Musonda P, M\u00e1trai Z, et al. Optimal treatment of the\n                    axilla after positive sentinel lymph node biopsy in early invasive breast\n                    cancer. Early results of the OTOASOR trial. [Az axilla optim\u00e1lis kezel\u00e9se\n                    pozit\u00edv \u0151rszemnyirokcsom\u00f3 eset\u00e9n korai invaz\u00edv eml\u0151r\u00e1kban. Az OTOASOR vizsg\u00e1lat\n                    el\u0151zetes eredm\u00e9nyei.] Orv Hetil. 2013; 154: 1934\u20131942.\n                    [Hungarian]","DOI":"10.1556\/OH.2013.29765"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Dorogi B, M\u00e1trai T, \u00dajhelyi M, et al. Assessing the needs of\n                    Hungarian breast cancer patients for modern oncoplastic breast surgical\n                    treatment. Questionnaire study of 500 patients. [A magyar eml\u0151r\u00e1kos betegek\n                    ig\u00e9nyei a korszer\u0171 onkoplasztikus eml\u0151seb\u00e9szeti ell\u00e1t\u00e1sra. 500 beteg k\u00e9rd\u0151\u00edves\n                    vizsg\u00e1lata.] Orv Hetil. 2020; 161: 1221\u20131228. [Hungarian]","DOI":"10.1556\/650.2020.31768"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Nagyk\u00e1lnai T, Nagy ACs, Landherr L. Postoperative radiotherapy of\n                    breast cancer and cardiotoxicity. [Posztoperat\u00edv eml\u0151besug\u00e1rz\u00e1s \u00e9s\n                    cardiotoxicitas.] Orv Hetil. 2014; 155: 897\u2013902. [Hungarian]","DOI":"10.1556\/OH.2014.29890"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, et al. Targeted\n                    therapy for breast cancer: an overview of drug classes and outcomes. Biochem\n                    Pharmacol. 2022; 204: 115209.","DOI":"10.1016\/j.bcp.2022.115209"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Kah\u00e1n Zs, Nikol\u00e9nyi A, Uhercs\u00e1k G, et al. Neoadjuvant systemic\n                    therapy in breast cancer. [Neoadjuv\u00e1ns sziszt\u00e9m\u00e1s ter\u00e1pia eml\u0151r\u00e1kban.] Orv\n                    Hetil. 2009; 150: 65\u201371. [Hungarian]","DOI":"10.1556\/oh.2009.28536"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Bo\u00e9r K. Adjuvant systemic therapy of early stage breast cancer. [A\n                    gy\u00f3gyszeres kezel\u00e9s szerepe a korai eml\u0151r\u00e1k kezel\u00e9s\u00e9ben.] Orv Hetil. 2010; 151:\n                    344\u2013353. [Hungarian]","DOI":"10.1556\/oh.2010.28824"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Koll\u00e1r R, Leel-\u0150ssy T, P\u00e1lffy V, et al. Review of bone health in\n                    women receiving endocrine therapy because of breast cancer. [Az eml\u0151r\u00e1k kezel\u00e9se\n                    sor\u00e1n alkalmazott hormonter\u00e1pia csonthat\u00e1sainak \u00e1ttekint\u00e9se.] Orv Hetil. 2024;\n                    165: 813\u2013821. [Hungarian]","DOI":"10.1556\/650.2024.33043"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Dankovics Zs, Ungv\u00e1ri T, Szab\u00f3 D, et al. Reducing the risk of\n                    radiation-induced cardiotoxicity in patients with left breast tumor. [A\n                    sug\u00e1rkezel\u00e9s okozta cardiotoxicitas kock\u00e1zat\u00e1nak cs\u00f6kkent\u00e9se bal oldali\n                    eml\u0151tumoros betegek kezel\u00e9se sor\u00e1n.] Orv Hetil. 2023; 164: 420\u2013425.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32740"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al. Prognostic role of\n                    neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and\n                    meta-analysis. J Natl Cancer Inst. 2014; 106: dju124.","DOI":"10.1093\/jnci\/dju124"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Deme D. Prognostic role of neutrophil-to-lymphocyte ratio determined\n                    by complete blood count in malignant diseases. [A v\u00e9rk\u00e9pb\u0151l meghat\u00e1rozott\n                    neutrophil-lymphocyta ar\u00e1ny prognosztikai \u00e9rt\u00e9ke daganatos betegs\u00e9gekben.] Orv\n                    Hetil. 2022; 163: 1066\u20131073. [Hungarian]","DOI":"10.1556\/650.2022.32507"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio\n                    (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients\n                    with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer\n                    2017; 111: 176\u2013181.","DOI":"10.1016\/j.lungcan.2017.07.024"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Yin JM, Zhu KP, Guo ZWet al. Is red cell distribution width a\n                    prognostic factor in patients with breast cancer? A meta-analysis. Front Surg.\n                    2023; 10: 1000522.","DOI":"10.3389\/fsurg.2023.1000522"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Lee HS, Jung EJ, Kim JM, et al. The usefulness of red blood cell\n                    distribution width and its ratio with platelet count in breast cancer after\n                    surgery and adjuvant treatment: a retrospective study. Gland Surg. 2022; 11:\n                    1864\u20131873.","DOI":"10.21037\/gs-22-410"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Abusanad A. Utilizing peripheral blood inflammatory biomarker (PBIB)\n                    to predict response to systemic therapy in patients with breast cancer. J Family\n                    Med Prim Care 2023; 12: 3368\u20133373.","DOI":"10.4103\/jfmpc.jfmpc_1125_23"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Mitrofanova I, Zavyalova M, Telegina N, et al. Tumor-associated\n                    macrophages in human breast cancer parenchyma negatively correlate with\n                    lymphatic metastasis after neoadjuvant chemotherapy. Immunobiology 2017; 222:\n                    101\u2013109.","DOI":"10.1016\/j.imbio.2016.08.001"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Yao D, Wang Z, Cai H, et al. Relationship between red cell\n                    distribution width and prognosis in patients with breast cancer after operation:\n                    a retrospective cohort study. Biosci Rep. 2019; 39:\n                    BSR20190740.","DOI":"10.1042\/BSR20190740"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Giuranno L, Ient J, De Ruysscher D, et al. Radiation-induced lung\n                    injury (RLI). Front Oncol. 2019; 9: 877.","DOI":"10.3389\/fonc.2019.00877"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-induced lung\n                    injury: assessment and management. Chest 2019; 156: 150\u2013162.","DOI":"10.1016\/j.chest.2019.03.033"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Arroyo-Hern\u00e1ndez M, Maldonado F, Lozano-Ruiz F, et al.\n                    Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021; 21:\n                    9.","DOI":"10.1186\/s12890-020-01376-4"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Dasgupta Q, Jiang A, Wen AM, et al. A human lung alveolus-on-a-chip\n                    model of acute radiation-induced lung injury. Nat Commun. 2023; 14:\n                    6506.","DOI":"10.1038\/s41467-023-42171-z"},{"key":"R28","unstructured":"Statisty . Free statistics app. Available from:\n                        https:\/\/statisty.app\/online-statistics-software [accessed:\n                    2023]."},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Chang S, Lv J, Wang X, et al. Pathogenic mechanisms and latest\n                    therapeutic approaches for radiation-induced lung injury: a narrative review.\n                    Crit Rev Oncol Hematol. 2024; 202: 104461.","DOI":"10.1016\/j.critrevonc.2024.104461"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"G\u00e1ldi \u00c1, Farkas G, Gazdag-Hegyesi S, et al. Combined biological\n                    effects of CBCT and therapeutic X-ray dose on chromosomal aberrations of\n                    lymphocytes. Radiat Oncol. 2024; 19: 109.","DOI":"10.1186\/s13014-024-02504-8"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Farkas Gy, Kocsis S Zs, Sz\u00e9kely G, et al. Quantifying biological\n                    effects of radiation from high-energy linear accelerators on lymphocytes. J\n                    Radiat Res. 2020; 61: 73\u201381.","DOI":"10.1093\/jrr\/rrz073"},{"key":"R32","unstructured":"Gazdag-Hegyesi Sz, G\u00e1ldi \u00c1, P\u00f3cza T, et al. Photon field junction\n                    for external beam radiotherapy of breast cancer involving axillary and\n                    supraclavicular lymph nodes. [Koplan\u00e1ris fotonmez\u0151k illeszt\u00e9se axillaris,\n                    illetve supraclavicularis nyirokcsom\u00f3k r\u00e9gi\u00f3j\u00e1t \u00e9rint\u0151 eml\u0151daganatok k\u00fcls\u0151\n                    besug\u00e1rz\u00e1s\u00e1n\u00e1l.] Magy Onkol. 2024; 68: 163\u2013168. [Hungarian]"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Schmitt M, Pin Y, Pflumio C, et al. Incidental axillary dose\n                    delivery to axillary lymph node levels I\u2013III by different techniques of\n                    whole-breast irradiation: a systematic literature review. Strahlenther Onkol.\n                    2021; 197: 820\u2013828.","DOI":"10.1007\/s00066-021-01808-y"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Davies C, Godwin J, Gray R, et al. Relevance of breast cancer\n                    hormone receptors and other factors to the efficacy of adjuvant tamoxifen:\n                    patient-level meta-analysis of randomised trials. Early Breast Cancer Trialists\u2019\n                    Collaborative Group (EBCTCG). Lancet 2011; 378: 771\u2013784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and\n                    mutagenesis. Environ Mol Mutagen. 2017; 58: 235\u2013263.","DOI":"10.1002\/em.22087"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Liu X, Chen Z. The pathophysiological role of mitochondrial\n                    oxidative stress in lung diseases. J Transl Med. 2017; 15: 207.","DOI":"10.1186\/s12967-017-1306-5"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Tang C, Gomez DR, Wang H, et al. Association between white blood\n                    cell count following radiation therapy with radiation pneumonitis in non-small\n                    cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 88:\n                    319\u2013325.","DOI":"10.1016\/j.ijrobp.2013.10.030"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Berg J, Halvorsen AR, Bengtson MB, et al. Circulating T cell\n                    activation and exhaustion markers are associated with radiation pneumonitis and\n                    poor survival in non-small-cell lung cancer. Front Immunol. 2022; 13: 1051156.\n                    Erratum: Front Immunol. 2022; 13: 875152.","DOI":"10.3389\/fimmu.2022.1051156"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Kuipers ME, van Doorn-Wink KC, Hiemstra PS, et al. Predicting\n                    radiation-induced lung injury in patients with lung cancer: challenges and\n                    opportunities. Int J Radiat Oncol Biol Phys. 2024; 118:\n                    639\u2013649.","DOI":"10.1016\/j.ijrobp.2023.10.044"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Kim KH, Pyo H, Lee H, et al. Association of T cell senescence with\n                    radiation pneumonitis in patients with non-small cell lung cancer. Int J Radiat\n                    Oncol Biol Phys. 2023; 115: 464\u2013475.","DOI":"10.1016\/j.ijrobp.2022.07.018"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Jakl L, Markov\u00e1 E, Kol\u00e1rikov\u00e1 L, et al. Biodosimetry of low dose\n                    ionizing radiation using DNA repair foci in human lymphocytes. Genes (Basel)\n                    2020; 11: 58.","DOI":"10.3390\/genes11010058"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Markov\u00e1 E, Somsed\u00edkov\u00e1 A, Vasilyev S, et al. DNA repair foci and\n                    late apoptosis\/necrosis in peripheral blood lymphocytes of breast cancer\n                    patients undergoing radiotherapy. Int J Radiat Biol. 2015; 91:\n                    934\u2013945.","DOI":"10.3109\/09553002.2015.1101498"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Sup\u00e1k D, Turi B, Kov\u00e1cs BG, et al. The predictive value of\n                    normal-range NLR (neutrophil-to-lymphocyte ratio) in SARS-CoV-2 infection during\n                    pregnancy. [A norm\u00e1ltartom\u00e1nyban marad\u00f3 NLR (neutrophil-lymphocyta ar\u00e1ny)\n                    predikt\u00edv \u00e9rt\u00e9ke a v\u00e1rand\u00f3ss\u00e1g alatt jelentkez\u0151 SARS-CoV-2-fert\u0151z\u00e9sben.] Orv\n                    Hetil. 2024: 165; 1039\u20131043. [Hungarian]","DOI":"10.1556\/650.2024.33065"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"T\u00f3th Z, Fadgyas-Freyler P, Tord\u00e9 \u00c1, et al. Complete blood count at\n                    the time of diagnosis is not predictive to survival in prostatic cancer.\n                    [Prosztatar\u00e1kban a v\u00e9rk\u00e9p a diagn\u00f3zis id\u0151pontj\u00e1ban nem predikt\u00edv a t\u00fal\u00e9l\u00e9sre.]\n                    Orv Hetil. 2024; 165: 1319\u20131324. [Hungarian]","DOI":"10.1556\/650.2024.33082"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Mitrea A, Postolache P, Man MA, et al. The profile of serum\n                    inflammatory biomarkers in patients with SARS-CoV-2 infection: how well do they\n                    reflect the presence of pulmonary involvement? [A gyullad\u00e1sos biomarkerek\n                    profilja SARS-CoV-2-fert\u0151z\u00e9sben szenved\u0151 betegekben: mennyire t\u00fckr\u00f6zik a\n                    t\u00fcd\u0151\u00e9rintetts\u00e9get?] Orv Hetil. 2023; 164: 1607\u20131615.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32880"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Deme D, Telekes A. Prognostic importance of plasma C-reactive\n                    protein (CRP) in oncology. [A C-reakt\u00edv protein (CRP) plazmaszintj\u00e9nek\n                    prognosztikai jelent\u0151s\u00e9ge az onkol\u00f3gi\u00e1ban.] Orv Hetil. 2017; 158: 243\u2013256.\n                    [Hungarian]","DOI":"10.1556\/650.2017.30646"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/29\/article-p1153.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/29\/article-p1153.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/29\/article-p1153.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:53:27Z","timestamp":1785423207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/29\/article-p1153.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":46,"journal-issue":{"issue":"29"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33336","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}